Stryker to Acquire Inari Medical in $4.9 Billion Deal

Stryker Corporation (NYSE: SYK), a global leader in medical technologies, announced on January 6, 2025, a definitive agreement to acquire Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, valuing the deal at approximately $4.9 billion. The acquisition aims to bolster Stryker’s position in the fast-growing venous thromboembolism (VTE) market, leveraging Inari’s innovative thrombectomy solutions for peripheral vascular diseases.

Inari, founded in 2011, specializes in mechanical thrombectomy devices used to treat conditions like deep vein thrombosis and pulmonary embolism. The company’s product portfolio is highly complementary to Stryker’s Neurovascular business, offering life-saving solutions without the use of thrombolytic drugs. VTE affects up to 900,000 people annually in the U.S., with higher risks during hospitalization, cancer treatment, and pregnancy.

Kevin Lobo, Chair and CEO of Stryker, stated,